GlassScriptPhysician profile
Kenneth A Stein
NPI 1760510630
$1,115.40
in general payments reported to CMS, 2019-2025
11 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.80 · 2020: $61.65 · 2021: $126 · 2022: $118 · 2023: $190 · 2024: $401 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $489.27 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $225.44 | 2020-2025 | Rocklatan, Clareon, Precision 7 |
| Sun Pharmaceutical Industries INC. | $121.01 | 2021-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $78.22 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $55.19 | 2024 | Rayone Emv, Rayone Spheric, Omidria |
| Bausch & Lomb Americas INC. | $47.02 | 2022-2023 | Infuse |
| Beaver-Visitec International, INC. | $26.88 | 2020 | |
| Oyster Point Pharma, INC. | $19.98 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $19.49 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.33 | 2020 | |
| Aerie Pharmaceuticals, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.